Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for enteroviruses ...

Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...

Drug design and development is expensive, often insufficient, and laced with the tendency for failure. Traditionally, it’s a hit-and-miss process that can stretch over a decade and consume around $2.3 ...

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. JPMorgan initiated the company at "Overweight" with a $65 price target, representing 80% potential upside ...

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, ...

With the world continuing to pack on pounds, there is an urgent need for effective weight management in an increasingly health-conscious world. According to an industry report, the global weight-loss ...

Shares of Structure Therapeutics (NASDAQ:GPCR) sank 35% in midday trading Monday after the company released Phase 2a data for its GLP-1 drug candidate GSBR-1290 in the treatment of obesity and ...